Literature DB >> 4016777

Interferon and doxorubicin in renal cell carcinoma.

H B Muss, C Welander, M Caponera, K Reavis, J M Cruz, M R Cooper, D V Jackson, F Richards, J J Stuart, C L Spurr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4016777

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

1.  Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial.

Authors:  F Porzsolt; D Messerer; R Hautmann; A Gottwald; H Sparwasser; K Stockamp; W Aulitzky; J G Moormann; K Schumacher; H Rasche
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

2.  Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.

Authors:  G Gasparini; S Dal Fior; F Pozza; G A Panizzoni; S Favretto; D D Von Hoff
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

3.  Pharmacokinetics of epirubicin in man. Non-influence of alpha interferon.

Authors:  S Eksborg; K Mattson
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

4.  A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study.

Authors:  B R Murphy; S M Rynard; L H Einhorn; P J Loehrer
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.